- Price is above Fair Value, showing premium demand versus the model.
EPRX
TOR
Week ended 07 Aug 2026
Weekly Investor Report
Eupraxia Pharmaceuticals Inc. · Healthcare · Biotechnology
Latest close
9.46 CAD
5.3%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -5.8% below the Trend Line and sits at 42.6% of its 52-week range. The latest completed week returned 5.3%, after a 0.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100.
Setup score
37
out of 100
Latest Close
9.46 CAD
7 Aug 2026
1W Return
5.3%
latest completed week
4W Return
0.0%
short-term follow-through
12W Return
-0.8%
quarterly tape
Trend Breadth
69.2%
36 of 52 weeks active
Volume Ratio
1.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
5.3%
Latest completed week; four-week move 0.0%.
Indicator stack
38/46
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
51/100
24 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -5.8% below the Trend Line and sits at 42.6% of its 52-week range. The latest completed week returned 5.3%, after a 0.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1512-week average 0.24
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.15Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 0.0% over four weeks, -0.8% over 12 weeks, and 31.2% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year36
Trend breadth69.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.35Latest activity-pressure read.
Pressure change27.0%Four-week change in activity pressure.
Leadership-9.98Latest relative-leadership reading.
RS change-31.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 61%
Model confidence 57%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value52/100Relative valuation strength. Underlying universe rank 49; rank 1 is best.
Quality53/100Profitability and accounting quality. Underlying universe rank 48; rank 1 is best.
Momentum54/100Medium-term price momentum. Underlying universe rank 47; rank 1 is best.
Growth54/100Revenue and earnings growth. Underlying universe rank 47; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -5.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -43.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -21.4% Net share repurchases relative to market value.
- Shareholder yield
- -21.4% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment51/100
Weighted news tone is neutral across 24 relevant articles.
5 positive · 18 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-26.4%Distance below the 52-week high.
13-week volatility7.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher14 of 2612 weeks finished lower.
Best week+9.2%Week of 31 Jul.
Worst week-16.1%Week of 5 Jun.
Latest week+5.3%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains9
Flat weeks0
Modest losses4
Sharp losses8
Recent vol7.0%13-week weekly-return volatility.
Base vol6.2%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew4.8% / -4.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorCA Healthcare
4-week rank23 / 46
Group average0.0%
Trend breadth34.8%
Trend34.8%active weekly trend signals
MD47.8%positive activity pressure
RS23.9%positive relative leadership
Four-week leaders
IndustryCA Biotechnology
4-week rank5 / 11
Group average-4.4%
Trend breadth18.2%
Trend18.2%active weekly trend signals
MD54.5%positive activity pressure
RS27.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape35/100
Trend, activity pressure, participation, and risk combine to a 35/100 tape read.
Indicator analysis11/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.15; No reversal markers Factors53/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 97; Small Cap Core rank 50 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment51/100Weighted news tone is neutral across 24 relevant articles.
Why Eupraxia Pharmaceuticals Inc stock is rising today Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 9.46 CAD | 5.3% | 10.04 CAD | 6.53 CAD | -0.35 | -9.98 | 199.0K | Off |
| 31 Jul 2026 | 8.98 CAD | 9.2% | 10.10 CAD | 6.52 CAD | -0.31 | -11.74 | 295.2K | Off |
| 24 Jul 2026 | 8.22 CAD | -11.3% | 10.15 CAD | 6.51 CAD | -0.35 | -19.62 | 337.7K | Off |
| 17 Jul 2026 | 9.27 CAD | -2.0% | 10.21 CAD | 6.50 CAD | -0.30 | -9.34 | 294.0K | Off |
| 10 Jul 2026 | 9.46 CAD | -0.7% | 10.20 CAD | 6.49 CAD | -0.48 | -7.59 | 278.8K | Off |
| 3 Jul 2026 | 9.53 CAD | 1.6% | 10.18 CAD | 6.49 CAD | -0.80 | -6.84 | 10.8K | Off |
| 26 Jun 2026 | 9.38 CAD | 3.5% | 10.14 CAD | 6.48 CAD | -1.03 | -7.68 | 187.9K | Off |
| 19 Jun 2026 | 9.06 CAD | 7.2% | 10.12 CAD | 6.48 CAD | -1.12 | -10.85 | 21.4K | Off |
| 12 Jun 2026 | 8.45 CAD | 1.4% | 10.12 CAD | 6.46 CAD | -1.13 | -16.60 | 11.1K | Off |
| 5 Jun 2026 | 8.33 CAD | -16.1% | 10.14 CAD | 6.46 CAD | -1.08 | -16.31 | 48.5K | Off |
| 29 May 2026 | 9.93 CAD | 2.4% | 10.12 CAD | 6.45 CAD | -0.93 | -0.99 | 237.3K | Off |
| 22 May 2026 | 9.70 CAD | 1.7% | 10.06 CAD | 6.43 CAD | -0.89 | -1.91 | 289.0K | Off |
| 15 May 2026 | 9.54 CAD | -7.5% | 9.99 CAD | 6.41 CAD | -0.94 | -1.19 | 169.4K | Off |
| 8 May 2026 | 10.31 CAD | -4.1% | 9.94 CAD | 6.40 CAD | -0.94 | 6.56 | 204.4K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.